Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.
The abnormal lymphocytes from patients with the Sezary syndrome produce macrophage migration inhibitory factors (MIF) both in vitro and in vivo. Five of six individuals studied had significant serum MIF activity and one had borderline activity. In contrast, in this study 47 normal individuals and 9 of 10 patients with extensive skin disease other than that of the Sezary syndrome had no such activity. Since the neoplastic T cells in patients with the Sezary syndrome localize in the skin, their production of chemical mediators in that site may be responsible for the generalized exfoliative erythroderma seen in that disease.
D000818:Animals; D002464:Cell Migration Inhibition; D002478:Cells, Cultured; D002845:Chromatography; D003873:Dermatitis, Exfoliative / Q000097:blood*; D003911:Dextrans; D006168:Guinea Pigs; D007645:Keratoderma, Palmoplantar / Q000097:blood; D008206:Lymphatic Diseases / Q000097:blood*; D008214:Lymphocytes / Q000276:immunology*; D008263:Macrophage Migration-Inhibitory Factors / Q000097:blood*; D008264:Macrophages / Q000276:immunology; D012871:Skin Diseases / Q000097:blood; D012882:Skin Tests; D013577:Syndrome
D003911:Dextrans; D008263:Macrophage Migration-Inhibitory Factors